| 摘要 |
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical compositions based on compounds of formulae (B), (D), (E) possessing the property of allosteric negative catalyst of CB1 receptor for use during treatment of a pathological condition or disorder selected from a group consisting of disorders of the urinary bladder and gastrointestinal tract; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; disorders caused by predilections, addictions, abuses and their relapses; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; and inflammatory and fibrous skin diseases.EFFECT: said compounds, by measure of metabolism, practically do not turn into active pregnenolone derivatives, which allows avoiding many side effects caused by use of orthosteric antagonists.20 cl, 4 tbl, 20 dwg, 29 ex |
